Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.

NCT02025010 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02025010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02025010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
January 27, 2014
Completion date
April 7, 2025
Enrollment
60 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer